Meeting ID: 827 6575 4554
Passcode: 463386
Dial by your location
+1 646 931 3860 US
+1 301 715 8592 US (Washington DC)
Speaker
Presenter: Humaira Siddiqi, MD, DFAPA
Humaira Siddiqi, MD, DFAPA is a practitioner and executive leader having deep connections across communities and organizations, and is
an educator holding clinical faculty appointments in the Washington, DC metropolitan area. She is incoming President of the Washington Psychiatric Society. Dr. Siddiqi completed her psychiatry residency as Chief Resident at Saint Elizabeths Hospital in Washington, DC. In 2012, Dr. Siddiqi joined the Mid-tlantic Permanente Medical group with Kaiser Permanente and became the Chief of Psychiatry for Virginia, and was subsequently appointed as the Regional Medical Director of Psychiatry for the Mid-Atlantic region, where she managed mental health teams responsible for a patient population of over 750,000 members across Washington, DC, Maryland, and Virginia. She developed programs in psychiatric urgent care, addiction medicine, women’s mood and anxiety disorders, interventional psychiatry (ECT, TMS, Ketamine), as well as systems and protocols in emerging therapeutics. Lastly, she completed her Psilocybin facilitator certification through the Integrative Psychiatric Institute in 2024 and her Advanced Certification in 2025. As a Board-certified psychiatrist, Dr. Siddiqi has been recognized as a Top Doctor by Washingtonian magazine for 7 years and by Northern Virginia magazine for 9 years.
For her contributions in the field of psychiatry, Dr. Siddiqi has also been honored by the American Psychiatric Association as a Distinguished Fellow. Now in private practice, she founded Kismet Psychiatry and Wellness LLC, bringing together her expertise in interventional psychiatry, integrative psychiatry, and psychotherapy within the field of emerging therapeutics.
Program Learning Objectives – At the conclusion of this activity, participants will be able to:
- Identify the Psychedelic Assisted therapy (PAT) models
- Recall the Bio-psycho-Social-Spiritual model of care
- Discuss common terminology unique to Psychedelic treatments and therapies
- Recognize the mechanism of action, general dosing, risks, benefits and side effects of Ketamine, Psilocybin and MDMA
Accreditation and Designation Statement
In support of improving patient care, this activity has been planned and implemented by American Psychiatric Association (APA) and Washington Psychiatric Society. The American Psychiatric Association (APA) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The American Psychiatric Association (APA) designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Instructions to Claim CME Credit will be emailed to you post meeting. Please be sure we have your preferred email address. Thank you for your valued participation.